The global pharmaceutical industry is one of the key profiteers of capitalism; it is estimated that in 2023 their annual revenue was 1.6 trillion USD. It is also one of the most corrupt industries in modern existence. Here is an overview of some of big pharma’s unethical practices.

Corruption of the Research Process

This is the most fundamental corruption, as it poisons the very well of scientific knowledge that doctors and regulators rely on.

· Designing Biased Studies: Companies design trials to maximize the chance of a favorable outcome.
· Using Weak Comparators: Testing a new drug against a placebo instead of the current best-existing treatment, making it look more effective than it really is.
· Wrong Dosages for Competitors: Giving the competing drug at too low a dose (making it look ineffective) or too high a dose (making it look more toxic).
· Short Trial Durations: Running trials for a short time to avoid detecting long-term side effects or to show a temporary benefit that fades.

Withdrawal effects: In studies of antipsychotics, one group of people who had previously been taking antipsychotics regularly, suddenly stop their “medication” cold turkey. This results in withdrawal effects as the brain had adjusted to the presence of the drug. This group is then compared to another group that continues taking their antipsychotic or another very similar antipsychotic. Therefore this group does not suffer from any withdrawal effects. Obviously, this just shows that suddenly stopping an antipsychotic results in various withdrawal effects. However, these studies claim that because the group which continued the drug had less short term negative effects than the group which quit cold turkey, that means that the antipsychotic is effective at treating psychosis, including in people who had never previously taken any drug.
· Selective Publication (Publication Bias): This is the “file drawer effect.” Overwhelmingly, studies with positive results are published, while those with negative or inconclusive results are buried.

· Impact: A meta-analysis of the published literature might show a drug is safe and effective, while the full, unpublished picture would tell a much different, more dangerous story. This gives doctors and regulators a completely false sense of a drug’s true risk-benefit profile.
· Ghostwriting and Guest Authorship:
· Ghostwriting: Company-hired medical writing firms draft the study manuscript. The named academic authors, who lend credibility, may have had little to do with the actual analysis or writing. The ghostwriter’s goal is to present the data in the most favorable light for the company.
· Guest Authorship: Prominent researchers are listed as authors as a “favor” or to increase the paper’s prestige, despite minimal contribution. This buys the company influence and lends the paper an air of independence it doesn’t deserve.
· Data Manipulation and Withholding: Companies have exclusive control over the raw data from their clinical trials. They can:
· Engage in “data dredging” – running endless statistical analyses until they find a positive-sounding result, even if it’s by chance.
· Refuse to share full data with independent researchers seeking to verify claims or conduct their own analyses.
· Hide or downplay alarming safety signals found in the data.

Manipulation of the Regulatory Approval Process

The FDA and other regulatory agencies are the gatekeepers, but this gate can be heavily influenced.

· The “Revolving Door”: There is a constant flow of personnel between the FDA and the pharmaceutical industry. High-level regulators are often hired by the companies they once regulated for their insider knowledge and connections. This can lead to a culture of leniency and a reluctance to be tough on former (or future) employers.
· “Stacking the Deck” in Advisory Committees: The FDA often relies on external expert committees to advise on drug approvals. Companies have been known to lobby for the inclusion of experts with known financial ties to their industry or who have previously expressed favorable views on their drug class.
· Publishing and Promoting “Seeding Trials”: These are studies disguised as legitimate science but whose primary purpose is to get doctors to prescribe a new drug. They are designed to be easy for doctors to enroll in (low risk) and serve as a marketing tool to build early prescription habits, not to answer a genuine scientific question.

Deceptive and Aggressive Marketing

Once a drug is approved, the goal is to maximize sales, often by expanding the market beyond the intended population.

· Off-Label Promotion: It is illegal for companies to actively market a drug for a use not approved by the FDA. However, they often do this indirectly by:
· Hiring “Key Opinion Leaders” (KOLs) – influential doctors paid to give talks to other doctors about unapproved uses.
· Sponsoring “continuing medical education” events that subtly promote off-label uses.
· Using their sales reps to hint at off-label benefits.
· Disease Mongering: This involves expanding the boundaries of illness to create new markets for drugs.
· Examples: Framing normal life experiences (like shyness) as “Social Anxiety Disorder” or mood fluctuations being mislabelled as “bipolar disorder” (especially bipolar II). This tactic is especially pervasive in psychiatry.
· Funding patient advocacy groups to agitate for recognition of a “disease” and promote the use of certain medications, spruiking their purported benefits and minimising the harms. They also may downplay the role of non-drug interventions (like lifestyle changes).
· Direct-to-Consumer Advertising (in the US and New Zealand): These ads emotionally manipulate patients into asking for specific, often expensive, brand-name drugs for conditions they may not truly have, putting pressure on doctors to prescribe them.
· Systematically Downplaying Harms: Marketing materials, sales reps, and published literature often minimize side effects, describing them as “rare” or “manageable,” even when the real-world data suggests they are more common and serious.

The Corruption of Medical Knowledge and Practice

This is about influencing the sources doctors trust to make decisions.

· Influence over “Key Opinion Leaders” (KOLs): Doctors are heavily influenced by their respected peers. Big Pharma identifies these KOLs and pays them massive “speaker’s fees,” “consulting fees,” and travel grants. These KOLs then become de facto, highly credible salespeople, presenting company-friendly data at conferences and in lectures.
· Capturing Medical Journals: Prestigious journals rely on reprint revenue. When a major study is published, the company buys hundreds of thousands of dollars worth of reprints to distribute. This creates a financial conflict of interest for the journal. Furthermore, journal advertising is a massive revenue stream.
· Writing the Treatment Protocols: Clinical practice guidelines, which dictate the standard of care for diseases, are supposed to be independent. However, a significant majority of the doctors on these panels have financial ties to the companies that make the drugs they are recommending. This effectively bakes the preference for expensive, new drugs into the standard of care, regardless of their merits.

Pricing and Patent Gaming

This is a different form of corruption that makes medicines inaccessible, prioritizing profit over public health.

· “Evergreening”: When a drug’s patent is about to expire, companies make minor, often clinically irrelevant changes (e.g., a new dosage, a combination with another drug) to get a new patent. This prevents cheap generic competition for years, keeping prices astronomically high.
· Product Hopping: Switching the market from an old formulation (e.g., a pill) to a new one (e.g., a slow-release capsule) just before the old version goes generic, and then aggressively marketing the “new and improved” version to make the generic seem obsolete.
· Pay-for-Delay: Brand-name companies pay generic manufacturers to delay the launch of their cheaper versions, a practice that is often anti-competitive and illegal but still occurs.

The Consequences

This system-wide corruption leads to:

· Patient Harm: People are prescribed drugs that are less effective and/or more dangerous than the published literature suggests. This results in countless deaths and permanent disability.
· Skyrocketing Costs: Healthcare systems and patients are burdened with enormous costs for drugs that don’t always represent a genuine therapeutic advance.
· Erosion of Trust: Rightly so, public trust in science, medicine, and doctors is severely damaged.
· Stifled Innovation: The incentive becomes to develop “me-too” drugs (slight variations on existing blockbusters) rather than truly novel, groundbreaking treatments for unmet needs.